When was Visiopharm founded?

Visiopharm was founded in 2001 and raised its 1st funding round 1 year after it was founded.

Where is Visiopharm located?

Visiopharm is headquartered in Horsholm, Denmark.

Which legal entities is Visiopharm associated with?

Visiopharm is associated with Visiopharm A/s.

How many employees does Visiopharm have?

As of Oct 31, 2026, the latest employee count at Visiopharm is 86.

Is Visiopharm a funded company?

Visiopharm is a funded company, having raised a total of $26.3M across 7 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Nov 12, 2002.

How much is Visiopharm worth?

The last known valuation of Visiopharm was $***** as of Jul 01, 2020.

When was the latest funding round of Visiopharm?

Visiopharm's latest funding was a $***** Series B round on Jul 01, 2020, with participation from 5 investors.

Where does Visiopharm rank among its competitors?

Visiopharm ranks 12th amongst 241 active competitors, of which 73 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was Techcyte, which secured $15M in Apr, 2026.

Who are the top competitors of Visiopharm?

Visiopharm's top competitors include PathAI, Aiforia and Proscia. Among them, Techcyte secured the most recent funding round in April, 2026.

Visiopharm - 2026 Company Profile, Team, Funding, Competitors & Financials

Visiopharm is an acquired company based in Horsholm (Denmark), founded in 2001 by Johan Dore and Michael Grunkin. It operates as a Developer of a SaaS and AI-based digital pathology solutions for image analysis and workflow standardization. Visiopharm has raised $26.3M in funding from Vaekstfonden and BankInvest, with last known valuation of $*****. The company has 241 active competitors, including 73 funded and 12 that have exited. Its top competitors include companies like PathAI, Aiforia and Proscia.

Company Details

Visiopharm is a developer of AI-based digital pathology solutions for image analysis and workflow standardization. The company offers three software solutions for clinicians and researchers. BioTopix is digital imaging software for analyzing pathology slides that have been tailored for drug researchers to enable biomarker discovery and quantification. Oncotopix uses a combination of virtual double staining and multiplexed biomarker tissue arrays for cancer diagnostics. Stereotopix is used to quantitatively analyze changes in tissue structure using Tissuealign. It also offers AI algorithms and a deep learning platform for better imaging solutions for diagnostic approaches and decision support.

Website: visiopharm.com
Social

Key Metrics

Founded Year

2001

Location

Horsholm, Denmark

Stage

Acquired

Total Funding

$26.3M in 7 rounds

Latest Funding Round

Series B, Jul 01, 2020, $*****

Last Known Valuation

$***** as on Jul 01, 2020

Investors

Vaekstfonden & 5 more

Ranked

12^th among 241 active competitors

Employee Count

86 as on Oct 31, 2026

Similar Companies

PathAI & 277 more

Exit Details

Acquired by Grundium (May 21, 2026)

View Visiopharm's full profile

Visiopharm is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Visiopharm A/s CIN: 26186676 , Denmark, Active	Jul 08, 2001	-	86 (As on Dec 31, 2021)

Visiopharm got acquired by Grundium on May 21, 2026.

Click here to take a look at Visiopharm's acquisition in detail

Visiopharm has raised a total funding of $26.3M over 7 rounds. Its first funding round was on Nov 12, 2002. Its latest funding round was a Series B round on Jul 01, 2020 for $*****. 5 investors participated in its latest round. Visiopharm has 6 institutional investors.

Here is the list of recent funding rounds of Visiopharm:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 01, 2020	8196362	Series B	1331048	4722968	6683318	2466890
Jul 06, 2018	6596815	Series B	8384290	8071777	9227299	ATP & 1 more
Nov 29, 2016	2305772	Series A	9075563	1415329	4868516	6777712

Access funding benchmarks and valuations. Sign up today!

View details of Visiopharm's funding rounds and investors

The founders of Visiopharm are Johan Dore and Michael Grunkin.

Here are the details of Visiopharm's key team members:

Johan Dore: Co-Founder & CTO of Visiopharm. They serve on the board of 1 company.
Michael Grunkin: Co-Founder & CEO of Visiopharm. They serve on the board of 1 company.

Visiopharm's Board of Directors

Visiopharm's board has 6 active members. Martin Bonde is part of team and Claus Henrik Nielsen, Patrik Olof Dahlén, Henrik Stender, Thomas Weilby Knudsen and Susanne Høiberg are independent board members.

Here is the list of Visiopharm's board of directors:

Name	Type	Representing	Status	Duration
Martin Bonde	Team	-	Current	8y 4m
dudgbka	Team	-	Past	7y 5m
wwjxngg	Team	-	Past	5y 9m
Claus Henrik Nielsen	Independent board member	-	Current	8y 4m
cy{tbfz	Independent board member	-	Current	3y 3m
dutjbhw	Independent board member	-	Current	3y 3m
buwqtbs	Independent board member	-	Current	3y 8m
jkf{sxb	Independent board member	-	Current	3y 6m

View details of Visiopharm's Founder profiles and Board Members

Visiopharm's employee count trend

Visiopharm has 86 employees as of Oct 26. Here is Visiopharm's employee count trend over the years:

Uncover Visiopharm's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Visiopharm include PathAI, Aiforia and Proscia. Here is the list of Top 10 competitors of Visiopharm, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	PathAI 2016, Boston (United States), Series C	Provider of digital pathology image management system for clinical labs	$255M	General Catalyst, General Atlantic & 22 others	72/100
2nd	Aiforia 2014, Helsinki (Finland), Public	Provider of an AI and cloud-based, deep learning image analysis platform in all therapy areas	$23M	Ascend Capital Partners, Businessfinland & 8 others	66/100
3rd	Proscia 2014, Philadelphia (United States), Acquired	Provider of an AI and cloud-based digital pathology solution for cancer diagnosis	$129M	Triangle Peak Partners, TEDCO & 22 others	62/100
4th	Techcyte 2014, Orem (United States), Series B	Artificial intelligence (AI) based image analysis platform for pathologists	$50.4M	ARUP Laboratories, Zoetis & 2 others	62/100
5th	Nucle AI 2017, Chicago (United States), Series B	AI-assisted platform for image analysis	$60M	Vertex Ventures Israel, Sanofi Ventures & 9 others	61/100
6th	Aignostics 2018, Berlin (Germany), Series B	Developer of artificial intelligence software for biomedical image analysis applications	$53.9M	Wellington Partners Venture Capital, Boehringer Ingelheim Venture Fund ... & 9 others	61/100
7th	Mindpeak 2017, Hamburg (Germany), Series A	Provider of AI-based pathological analysis platform	$18.3M	IFB Innovationsstarter, ZEISS & 28 others	59/100
8th	Onc.ai 2020, San Carlos (United States), Series A	AI-based cancer treatment and diagnosis platform for healthcare providers	$31M	Accomplice, MassMutual & 12 others	57/100
9th	HistoIndex 2010, Singapore (Singapore), Series A	Provider of AI powered digital pathology platform for fibrosis analysis	$6.89M	OCBC, SEEDS Capital & 2 others	57/100
10th	Deciphex 2017, Dublin (Ireland), Series C	Network of pathologists providing digital diagnostic services for medical testing	$56.6M	Seroba Life Sciences, Molten Ventures & 13 others	56/100
12th	Visiopharm 2001, Horsholm (Denmark), Acquired	Developer of a SaaS and AI-based digital pathology solutions for image analysis and workflow standardization	$26.3M	ATP, Northcap Partners & 4 others	56/100